Atlas Trials

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Clinical trial NCT04041284 · COMPLETED

Trial details

NCT number
NCT04041284
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
MigraineMajor Depressive Disorder
Start date
2019-09-13
Primary completion
2022-08-31
Enrollment
353

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.